RenovaCare products are under development and not approved for sale in the United States.

Results may vary from person to person.

RenovaCare products are under development and not approved for sale in the United States.
Results may vary from person to person.

RenovaCare Responds to SEC Complaint

Roseland, NJ – June 1st, 2021 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com) today announced that it intends to vigorously defend itself and its stockholders against allegations made by the U.S. Securities and Exchange Commission (“SEC”) in a civil complaint filed on May 28, 2021 regarding legacy events (the “Complaint”) from over 3 years ago.

RenovaCare to Present at H.C. Wainwright Global Life Science Conference March 9-10, 2021

Roseland, NJ – February 25th, 2021 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), a clinical-stage developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, announced today that the Company will present at the 2021 H.C. Wainwright Global Life Sciences Conference, scheduled for March 9 – 10.

RenovaCare to Present at Noble Capital Markets Annual Investor Conference on January 19, 2021

Roseland, NJ – January 19, 2021 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), a clinical-stage developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, announced today that the Company will present at NobleCon17 – Noble Capital Markets’ Seventeenth Annual Investor Conference on Tuesday, January 19 at 5:15pm EST. The conference is virtual, with no cost, obligation or restrictions to attend: www.noblecon17.com.

RenovaCare Chairman Discusses 2020 Highlights and Provides 2021 Outlook

Roseland, NJ – December 22, 2020 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), a clinical-stage developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, announced today that it has issued the following year-end letter from its Chairman and CEO, Alan L. Rubino to the Company’s stockholders and interested parties: